ReviewOxford open immunology2021
The role and uses of antibodies in COVID-19 infections: a living review.
Review in Oxford open immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.Frontiers in immunology · 2021Trial
- Expression, Purification, and Application of SARS-CoV-2 Nucleocapsid Protein for Serological Detection of IgG and IgM Antibodies.Avicenna journal of medical biotechnology · 2026Article
- Humoral and Cellular Immune Responses Against SARS-CoV-2 Following COVID-19 Vaccination in Older Adults: A Systematic Review.Vaccines · 2025Review
- Modeling Antibody Kinetics Post-mRNA Booster Vaccination and Protection Durations Against SARS-CoV-2 Infection.Journal of medical virology · 2025Article
- A Multi-Center Prospective Study on Post-Vaccination Humoral Response to SARS-CoV-2 in Polish Long-Term Care Facility Residents: Associations with COVID-19 Clinical Course and Comorbidities.Infectious disease reports · 2025Article
- SARS-CoV-2 Vaccine-Induced Humoral Immunity in Immunocompetent European Adults: A Systematic Review.Microorganisms · 2025Review
- Article
- Short-chain fatty acids play a key role in antibody response to SARS-CoV-2 infection in people living with HIV.Scientific reports · 2024Article
- Innate immune response in COVID-19: single-cell multi-omics profile of NK lymphocytes in a clinical case series.Cell communication and signaling : CCS · 2024Article
- The Seraph 100Antibodies (Basel, Switzerland) · 2024Article
- Excretion of SARS-CoV-2 RNA in feces has no prognostic benefit in the outcome of COVID-19: A clinical and immunological study.Biomolecules & biomedicine · 2024Article
- SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines.Vaccines · 2023Review
- Inhalation of virus-loaded droplets as a clinically plausible pathway to deep lung infection.Frontiers in physiology · 2023Article
- Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications.Frontiers in immunology · 2023Review
- The SARS-CoV-2 Antibodies, Their Diagnostic Utility, and Their Potential for Vaccine Development.Vaccines · 2022Review
- Article
- Electrochemical Immunoassay for the Detection of SARS-CoV-2 Nucleocapsid Protein in Nasopharyngeal Samples.Analytical chemistry · 2022Article
- COVID-19 patients exhibit unique transcriptional signatures indicative of disease severity.Frontiers in immunology · 2022Article
- Circulating IgG Levels in SARS-CoV-2 Convalescent Individuals in Cyprus.Journal of clinical medicine · 2021Article
- Communication pathways bridge local and global conformations in an IgG4 antibody.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
Coronavirus disease 2019 has generated a rapidly evolving field of research, with the global scientific community striving for solutions to the current pandemic. Characterizing humoral responses towards SARS-CoV-2, as well as closely related strains, will help determine whether antibodies are central to infection control, and aid the design of therapeutics and vaccine candidates. This review outlines the major aspects of SARS-CoV-2-specific antibody research to date, with a focus on the various prophylactic and therapeutic uses of antibodies to alleviate disease in addition to the potential of cross-reactive therapies and the implications of long-term immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.